NeonMind Biosciences Inc (LCR) AI Stock Analysis

• Market Cap: C$4.57M
• Dividend Yield: N/A
• Average Volume (3M): 159.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: N/A
• EPS Growth: 20.30%
• Country: CA
• Employees: 28
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Industrial Materials
• EPS (TTM): >-0.01
• Shares Outstanding: 91,440,870
• 10 Day Avg. Volume: 86,772
• 30 Day Avg. Volume: 159,138
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

NeonMind Biosciences Inc exhibits a challenging financial situation with no revenue, high leverage, and negative cash flows, significantly impacting its overall score. Technical analysis provides some stability signals, but the lack of valuation metrics suggests caution. The overall risk profile suggests a need for strategic changes or additional funding to improve its financial health.

NeonMind Biosciences Inc Business Overview & Revenue Model

Company Description

Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.

How the Company Makes Money

NeonMind Biosciences Inc generates revenue primarily through the development and commercialization of psychedelic-based therapies. The company seeks to advance its drug candidates through clinical trials and secure regulatory approvals, which can lead to partnerships or licensing agreements with larger pharmaceutical companies. These partnerships may provide upfront payments, milestone payments, and royalties on future sales. Additionally, NeonMind may explore opportunities in other sectors such as wellness products or services that align with its core focus on mental health, although specific details on these revenue streams are currently unavailable.

NeonMind Biosciences Inc Financial Statement Overview

Summary

NeonMind Biosciences Inc is facing significant financial challenges, with no current revenue generation, high leverage, and negative cash flows. This suggests a high-risk financial situation with potential liquidity issues and a need for strategic turnaround or additional funding to sustain operations.

Income Statement

NeonMind Biosciences Inc has reported no revenue in the most recent periods, indicating a lack of sales activity or operational revenue. The absence of gross profit, EBIT, and EBITDA suggests ongoing operational losses, while net income figures are unavailable for the latest period, implying a continuation of negative profitability trends seen in past reports.

Balance Sheet

The balance sheet reflects a challenging financial position with negative stockholders' equity, indicating liabilities exceed assets. The company has a high debt load relative to its equity, and negative equity raises solvency concerns, highlighting significant financial risk.

Cash Flow

The cash flow statement shows persistent negative free cash flow and operating cash flow, indicating cash outflows exceed inflows, which could impact liquidity. Financing activities are positive, suggesting reliance on external funding to maintain operations.

Breakdown	TTM	Mar 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	415.80K
Gross Profit	0.00	0.00	0.00	0.00	415.55K
EBITDA	16.14K	―	-1.75M	-7.83M	-1.06M
Net Income	-1.58M	―	-2.03M	-7.21M	-2.68M
Balance Sheet
Total Assets	0.00	719.33K	129.43K	1.34M	209.90K
Cash, Cash Equivalents and Short-Term Investments	0.00	135.40K	69.91K	967.27K	1.17K
Total Debt	0.00	1.04M	846.94K	450.01K	691.25K
Total Liabilities	0.00	1.33M	1.53M	1.05M	987.31K
Stockholders Equity	5.30M	-612.89K	-1.40M	290.30K	-777.41K
Cash Flow
Free Cash Flow	-891.22K	-1.31M	-1.22M	-5.82M	-853.45K
Operating Cash Flow	-732.95K	-1.13M	-1.08M	-5.82M	-853.45K
Investing Cash Flow	-168.02K	-36.15K	72.14K	389.12K	0.00
Financing Cash Flow	526.68K	627.93K	271.00K	6.20M	746.93K

NeonMind Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LCR.

NeonMind Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RVV	46 Neutral	6.28M	-1.56	0.00%	―	0.00%	15.79%
NUMI	41 Neutral	13.86M	-0.45	-2707.75%	―	0.00%	0.00%
TRIP	41 Neutral	14.43M	-3.89	-21.78%	―	-8.27%	50.55%
CYBN	37 Underperform	1.97M	-0.02	0.00%	―	0.00%	11.58%
LCR	29 Underperform	C$4.57M	―	0.00%	―	―	20.30%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%